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Abstract
Background: The results from the published studies on the association between hypoxia-inducible
factor -1  (HIF-1α) polymorphisms and cancer risk are conflicting. In this meta-analysis, we aimed
to investigate the association between HIF-1  1772 C/T and 1790 G/A polymorphisms and cancer.
Methods: The meta-analysis for 1772 C/T polymorphism included 4131 cancer cases and 5387
controls, and for 1790 G/A polymorphism included 2058 cancer cases and 3026 controls. Allelic
and genotypic comparisons between cases and controls were evaluated. Subgroup analyses by
cancer types, ethnicity, and gender were also performed. We included prostate cancer in male
subgroup, and female specific cancers in female subgroup.
Results: For the 1772 C/T polymorphism, the analysis showed that the T allele and genotype TT
were significantly associated with higher cancer risk: odds ratio (OR) = 1.29 [95% confidence
interval (CI, 1.01, 1.65)], P = 0.04, Pheterogeneity < 0.00001, and OR = 2.18 [95% CI (1.32, 3.62)], P =
0.003, Pheterogeneity = 0.02, respectively. The effect of the genotype TT on cancer especially exists in
Caucasians and female subjects: OR = 2.40 [95% CI (1.26, 4.59)], P = 0.008, Pheterogeneity = 0.02, and
OR = 3.60 [95% CI (1.17, 11.11)], P = 0.03, Pheterogeneity = 0.02, respectively. For the 1790 G/A
polymorphism, the pooled ORs for allelic frequency comparison and dominant model comparison
suggested a significant association of 1790 G/A polymorphism with a decreased breast cancer risk:
OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, Pheterogeneity = 0.45, and OR = 0.29 [95% CI (0.09, 0.97)],
P = 0.04, Pheterogeneity = 0.41, respectively. The frequency of the HIF-1  1790 A allele was very low
and only two studies were included in the breast cancer subgroup.
Conclusions: Our meta-analysis suggests that the HIF-1  1772 C/T polymorphism is significantly
associated with higher cancer risk, and 1790 G/A polymorphism is significantly associated with
decreased breast cancer risk. The effect of the 1772 C/T polymorphism on cancer especially exists
in Caucasians and female subjects. Only female specific cancers were included in female subgroup,
which indicates that the 1772 C/T polymorphism is significantly associated with an increased risk
for female specific cancers. The association between the 1790 G/A polymorphism and lower breast
cancer risk could be due to chance.
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Cancer is one of the leading causes of death in the world.
It has become a worldwide public health problem [1]. The
exact mechanism of carcinogenesis is not yet fully eluci-
dated [2]. Recently, it has become clear that genetic varia-
tion contributes to the development and progression of
cancer [2,3]. However, due to various reasons, including
considerable heterogeneity of the disease, the identifica-
tion of susceptibility genes is difficult and most associa-
tions have not been replicated.
Intratumoral hypoxia is a hallmark of solid cancer [4]. A
hypoxic microenvironment initiates multiple cellular
responses, such as proliferation and angiogenesis, result-
ing in the development and progression of cancer [4].
Hypoxia-inducible factor -1 (HIF-1) is a key transcription
factor that regulates cellular response to hypoxia [5,6].
Studies have demonstrated that HIF-1 plays important
roles in the development and progression of cancer
through activation of various genes that are involved in
crucial aspects of cancer biology, including angiogenesis,
energy metabolism, vasomotor function, erythropoiesis,
and cell survival [5,6]. HIF-1 is a heterodimeric transcrip-
tion factor consisting of α and β subunits [5,6]. The β sub-
unit is constitutively expressed and the α subunit which
determines HIF-1 activity is regulated by oxygen tension.
Hypoxia- inducible factor -1α (HIF-1α) is hydroxylated
and degraded rapidly under normoxic conditions through
von Hippel-Lindau mediated ubiquitin-proteasome path-
way whereas it becomes stabilized and is rapidly accumu-
lated in cell under hypoxic conditions [5,6]. Recent
studies have shown overexpression of HIF-1α in many
human cancers with an advanced tumor grade, implying
HIF-1α as an independent prognostic factor of cancer [7].
HIF-1  gene polymorphisms have been investigated for a
possible role in mediating genetic predisposition to can-
cer [8]. Recently, two single nucleotide polymorphisms
(SNPs) of human HIF-1  gene, HIF-1  1772 C/T
(rs11549465) and 1790 G/A (rs rs11549467), which
result in proline to serine and alanine to threonine amino
acid substitutions, respectively, were identified. Both of
them are located within exon 12 of the HIF-1  gene [5,6].
The presences of these polymorphic variants were shown
to cause a significantly higher transcriptional activity than
the activity of the wild type in vitro studies under both
normoxic and hypoxic conditions [5,6]. Moreover, both
of the polymorphisms were associated with increased
tumor microvessel density, thus contributing to the devel-
opment and progression of cancer [5,6]. A number of
investigators have studied the possible association
between the HIF-1  polymorphisms and cancer risk, but
the results have been conflicting [5,6,8-22]. Thus, the
association between the HIF-1  1772 C/T and 1790 G/A
polymorphisms and cancer requires further investigation.
In this paper, a meta-analysis was performed on previous
reports to investigate the association of HIF-1  1772 C/T
and 1790 G/A polymorphism with cancer.
Materials and methods
Identification and eligibility of relevant studies
All studied published before June 2009 that investigated
the association between the HIF-1  1772 C/T and 1790 G/
A polymorphisms with cancer were considered in the
meta-analysis. A systematic search of the literature was
carried out by using PubMed. The language was limited to
English. The keywords used for this search were "HIF-1
OR hypoxia-inducible factor-1" concatenated with "poly-
morphism OR variant OR SNP OR mutation" AND "can-
cer OR tumor OR carcinoma OR malignancy". Only the
studies with complete data on comparison of frequency of
the HIF-1  1772 C/T and 1790 G/A gene polymorphisms
between controls and patients with cancer were selected.
Animal studies, case reports, review articles, abstracts, edi-
torials, reports with incomplete data, and studies based
on pedigree data were excluded.
Data extraction
Two investigators independently reviewed the articles to
exclude irrelevant and overlapping studies. The results
were compared, and disagreements were resolved by dis-
cussion and consensus. When overlapping articles were
found, we only included the publication that reported the
most extensive information. From each study, the follow-
ing information was extracted: journal, year of publica-
tion, first author, demographics, racial background of the
study population, validity of the genotyping method,
matching, and the number of cases and controls for each
genotype. Frequencies of alleles were calculated for the
cases and the controls, from the corresponding genotype
distributions.
Statistical analysis
Review Manager 5.0 software (The Cochrane Collabora-
tion, Oxford, UK) was used for meta-analysis. The follow-
ing genotype contrasts for the HIF-1  1772 C/T
polymorphism were evaluated: homozygotes TT versus a
combination of CT and CC [TT versus (CT+CC), recessive
model], a combination of TT and CT versus CC [(TT+CT)
versus CC, dominant model]. Contrast of C allelic fre-
quency versus G allelic frequency (C versus G) was also
evaluated. A allele of the HIF-1  1790 G/A polymorphism
was very rare. In most of the studies, homozygote AA was
totally absent in both case and controls. For the HIF-1
1790 G/A polymorphism, we only performed allelic fre-
quency comparison (A versus G) and dominant model
comparison [(AA+AG) versus GG]. In addition, we con-
ducted subgroup analyses by cancer types, ethnicity, and
gender. For gender subgroups, we included prostate can-
cer in male subgroup, and female specific cancers such asPage 2 of 10
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vix cancer in female subgroup. We only conducted the
meta-analysis on the subgroup with more than two stud-
ies in Hardy-Weinberg equilibrium (HWE). For the HIF-1
1790 G/A polymorphism, the pooled effects for other can-
cers (exclusion of the study on breast cancer) were also
performed.
The existence of heterogeneity between studies was ascer-
tained by Q-statistic. The pooled odds ratio (OR) was esti-
mated with models based on fixed effects or random
effects assumptions. If the significant Q statistic (P < 0.1)
indicated heterogeneity across studies, a random effects
model was used for meta-analysis. Otherwise, a fixed
effect model was selected. The 95% confidence interval
(CI) of OR was also calculated. The distributions of geno-
types in the controls were checked for HWE. Studies with
the controls not in HWE were subjected to a sensitivity
analysis [23].
The publication bias among the studies from the cases ver-
sus controls was assayed. Funnel plots of the HIF-1  1772
C/T polymorphism for T versus C and HIF-1  1790 G/A
polymorphism for A versus G were performed to look for
evidence of publication bias. The funnel plot should be
asymmetric when there is publication bias and symmetric
in the case of no publication bias. Egger's test, estimated
by MIX 1.7 software (Kitasato Clinical Research Center,
Kitasato University, Japan), was performed to measure the
funnel plot asymmetry [24-26].
Results
Eligible studies
The flow diagram illustrates the main reasons for studies
exclusion (Additional file 1). The selected study character-
istics were summarized in Additional file 2. 16 relevant
case-control studies concerning the HIF-1  1790 G/A and
1772 C/T polymorphisms and cancer were included in the
meta-analysis. In all 16 studies, there were 9 studies of
Caucasians, 5 studies of East Asians, 2 studies of mixed
ethnicity. The 16 studies included 4 studies on prostate
cancer, 3 studies on breast cancer, 2 studies on colorectal
carcinoma, 2 studies on renal cell carcinoma, 1 studies on
endometrial cancer, 1 study on early stage of oral squa-
mous cell carcinoma, 1 study on ovarian cancer, endome-
trial cancer, and cervical cancer, 1 study on esophageal
squamous cell carcinoma, and 1 study on head and neck
squamous cell carcinoma. The samples only consisted of
females in 7 studies, only consisted of males in 4 studies,
and consisted of both females and males in 5 studies. In
the eligible studies, all the 16 studies presented the data
on the 1772 C/T polymorphism, 10 studies presented the
data on the 1790 G/A polymorphism. For the 1772 C/T
polymorphism, the distributions of the genotypes in the
control groups in 5 studies were not in HWE. For the 1790
G/A polymorphism, the distributions of the genotypes in
control groups in 1 study were not in HWE. In all the eli-
gible studies, 1 study provided data on three kinds of can-
cers (endometrial cancer, ovarian cancer, and cervical
cancer) and both of the polymorphisms. Thus, each type
of cancer in the study was treated as a separate study in
this meta-analysis. In the eligible studies, 7 studies stated
that the age, gender status or other variables were matched
between the cases and controls, 1 paper just stated the
controls were matched within constraints and did not
describe the variables in detail, and 8 studies did not
clearly state the use of a matching design for cases during
the selection process of controls. Genotyping methods
used in the eligible studies included PCR-restriction frag-
ment length polymorphism (PCR-RFLP), direct sequenc-
ing, PCR-single strand conformational polymorphism
(PCR-SSCP), and SNP-IT™ assays. Only 11 studies men-
tioned quality control of the genotyping, such as blind-
ness to the case-control status, random repeat, or
validation using a different genotyping method. The gen-
otype and allele distribution of the HIF-1  1772 C/T and
1790 G/A polymorphisms of individual studies were sum-
marized in Additional file 3.
Summary statistics
The meta-analysis for the HIF-1  1772 C/T polymorphism
included 4131 cancer cases and 5387 controls. In both
case group and control group, allele C was the most fre-
quent, and the prevalence of the CC genotype was the
highest, whilst the prevalence of the TT genotype was the
lowest (Additional file 2, 3).
The meta-analysis for the HIF-1  1790 G/A polymorphism
included 2058 cancer cases and 3026 controls. In both
case group and control group, allele G was the most fre-
quent, and the prevalence of the GG genotype was the
highest, whilst the prevalence of the AA genotype was the
lowest (Additional file 2, 3).
Association of the HIF-1  1772 C/T polymorphism with 
cancer risk
We first performed the meta-analysis on all 18 studies.
The pooled ORs for allelic frequency comparison and
recessive model comparison suggested that the T allele
and genotype TT were significantly associated with an
increased cancer risk: OR = 1.29 [95% CI (1.01, 1.65)], P
= 0.04, Pheterogeneity < 0.00001, and OR = 2.18 [95% CI
(1.32, 3.62)], P = 0.003, Pheterogeneity = 0.02, respectively
(Table 1, Figure 1). We then performed the subgroup anal-
yses stratified by cancer types, ethnicity and gender. The
pooled ORs for allelic frequency comparison and domi-
nant model comparison suggested the 1772 C/T polymor-
phism was significantly associated with an increased
prostate cancer risk: OR = 1.78 [95% CI (1.07, 2.94)], P =
0.03, Pheterogeneity < 0.0001, and OR = 1.85 [95% CI (1.04,Page 3 of 10
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1). The association between the genotype TT and
increased cancer susceptibility was significant in Cauca-
sians and in female subjects: OR = 2.40 [95% CI (1.26,
4.59)], P = 0.008, Pheterogeneity = 0.02, and OR = 3.60 [95%
CI (1.17, 11.11)], P = 0.03, Pheterogeneity = 0.02 (Table 1,
Figure 2, 3). A marginal significant association between
the 1772 C/T polymorphism and increased cancer risk
was detected in East Asians under recessive model: OR =
5.31 [95% CI (0.91, 30.83)], P = 0.06, Pheterogeneity = 0.76
(Table 1). The remaining pooled ORs from this analysis
were not significant (P > 0.05) (Table 1).
Sensitivity analysis was next performed by excluding the
studies with controls not in HWE. The results from the
allelic frequency comparison and dominant model com-
parison showed no evidence that the 1772 C/T polymor-
phism was significantly associated with an increased
prostate cancer risk: OR = 1.68 [95% CI (0.94, 3.02)], P =
0.08, Pheterogeneity < 0.0001, and OR = 1.75 [95% CI
(0.89, 3.47)], P = 0.11, Pheterogeneity < 0.0001, respec-
tively (Table 1). The association between the genotype TT
and the increased cancer risk was marginally significant in
Caucasians and in female subjects: OR = 3.35 [95% CI
(1.01, 11.11)], P = 0.05, Pheterogeneity = 0.01, and OR =
3.88 [95% CI (0.94, 16.01)], P = 0.06, Pheterogeneity =
0.01, respectively (Table 1, Figure 2, 3). The other results
were similar to those when the studies with controls not
in HWE were included (Table 1).
There was significant heterogeneity among the available
studies (Table 1). To detect the source of the heterogene-
Table 1: Meta-analysis of the HIF-1α 1772 C/T polymorphism and cancer association.
Genetic contrasts Group and subgroups
under analysis







T versus C Overall 18 <0.00001 Random 1.29 (1.01, 1.65) 0.04
Overall in HWE 13 <0.00001 Random 1.39 (1.02, 1.90) 0.04
Caucasian 11 <0.00001 Random 1.33 (0.90, 1.97) 0.15
Caucasian in HWE 7 <0.00001 Random 1.69 (0.94, 3.04) 0.08
East Asian 5 0.16 Fixed 1.05 (0.84, 1.30) 0.69
Female* 7 <0.00001 Random 1.39 (0.83, 2.35) 0.21
Female in HWE* 6 <0.00001 Random 1.48 (0.81, 2.71) 0.20
Male (prostate cancer)** 4 <0.0001 Random 1.78 (1.07, 2.94) 0.03
Male (prostate cancer)
in HWE**
3 <0.0001 Random 1.68 (0.94, 3.02) 0.08
Breast cancer 3 0.12 Fixed 0.99 (0.79, 1.23) 0.90
Colorectal cancer 2 0.02 Random 0.26 (0.01, 6.38) 0.41
TT versus (CT+CC) Overall 18 0.02 Random 2.18 (1.32, 3.62) 0.003
Overall in HWE 13 0.002 Random 2.87 (1.14, 7.26) 0.03
Caucasian 11 0.02 Random 2.40 (1.26, 4.59) 0.008
Caucasian in HWE 7 0.01 Random 3.35 (1.01, 11.11) 0.05
East Asian 5 0.76 Fixed 5.31 (0.91, 30.83) 0.06
Female* 7 0.02 Random 3.60 (1.17, 11.11) 0.03
Female in HWE* 6 0.01 Random 3.88 (0.94, 16.01) 0.06
Male (prostate cancer)** 4 0.1 Fixed 1.53 (0.90, 2.60) 0.11
Male (prostate cancer)
in HWE**
3 0.04 Random 1.78 (0.41, 7.74) 0.44
Breast cancer 3 0.10 Fixed 1.51 (0.55, 4.11) 0.42
Colorectal cancer 2 - Random 1.97 (0.33, 11.90) 0.46
(TT+CT) versus CC Overall 18 <0.00001 Random 1.19 (0.88, 1.59) 0.26
Overall in HWE 13 <0.00001 Random 1.34 (0.97, 1.85) 0.08
Caucasian 11 <0.00001 Random 1.15 (0.68, 1.93) 0.61
Caucasian in HWE 7 <0.00001 Random 1.70 (0.89, 3.26) 0.11
East Asian 5 0.15 Fixed 1.01 (0.80, 1.27) 0.96
Female* 7 0.0004 Random 1.28 (0.76, 2.15) 0.35
Female in HWE* 6 0.0002 Random 1.41 (0.77, 2.57) 0.26
Male (prostate cancer)** 4 <0.0001 Random 1.85 (1.04, 3.31) 0.04
Male (prostate cancer)
in HWE**
3 <0.0001 Random 1.75 (0.89, 3.47) 0.11
Breast cancer 3 0.22 Fixed 0.96 (0.76, 1.21) 0.75
Colorectal cancer 2 0.02 Random 0.25 (0.01, 5.99) 0.39
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
* Only female specific cancers were included in the female subgroup.
** All male patients were the patients with prostate cancer.Page 4 of 10
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types, and ethnicity. The results showed studies in female
subject subgroup and Caucasian subgroup were the main
contributors of heterogeneity (Table 1).
Association of the HIF-1  1790 G/A polymorphism with 
cancer risk
The results on all 12 studies showed no evidence that the
HIF-1  1790 G/A polymorphism was significantly associ-
ated with an increased cancer risk (P > 0.05) (Table 2, Fig-
ure 4). The significant association between the A allele
and the increased cancer risk was detected in other can-
cers: OR = 2.31 [95% CI (1.12, 4.75)], P = 0.02, Pheterogene-
ity = 0.0004 (Table IV) (Table 2). A marginal association
between the 1790 G/A polymorphism and the increased
cancer risk in other cancers was also detected under dom-
inant model: OR = 2.22 [95% CI (0.95, 5.20)], P = 0.06,
Pheterogeneity < 0.00001 (Table 2). The pooled ORs for
allelic frequency comparison and dominant model com-
parison suggested the 1790 G/A polymorphism was sig-
nificantly associated with an increased cancer risk in
Caucasians: OR = 3.08 [95% CI (1.49, 6.36)], P = 0.002,
Pheterogeneity = 0.04, and OR = 2.60 [95% CI (1.03, 6.59)],
P = 0.04, Pheterogeneity = 0.002, respectively (Table 2). How-
ever, reanalysis after exclusion the studies with controls
not in HWE did not suggest these associations (P > 0.05)
(Table 2). The pooled ORs for A versus G and (AA+AG)
versus GG suggested that 1790 G/A polymorphism was
significantly associated with a decreased breast cancer risk:
OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, Pheterogeneity =
0.45, and OR = 0.29 [95% CI (0.09, 0.97)], P = 0.04, Phet-
erogeneity = 0.41, respectively (Table 2, Figure 4). The
remaining pooled ORs on the association of 1790 G/A
polymorphism and cancer risk were not significant (P >
0.05) (Table 2).
There was significant heterogeneity for allelic frequency
comparison and dominant model comparison among the
available studies (Table 2). However, the heterogeneity
was effectively decreased or removed in the subgroups
stratified by gender, ethnicity, and cancer types (Table 2).
Publication bias
Publication bias was assayed by visual funnel plot inspec-
tion and Egger's test. The funnel plots for T versus C were
basically symmetric (Additional file 4A) and Egger's test
did not indicate asymmetry of the plot [Intercept =
0.5092, 95% CI (-1.5454, 2.5639), P = 0.6065]. The fun-
nel plots for A versus G showed some asymmetry that
could suggest the existence of publication bias (Addi-
tional file 4B). However, Egger's test did not show statisti-
cal evidence for publication bias [Intercept = -1.82, 95%
CI (-4.1611, 0.5212), P = 0.1108].
Discussion
HIF-1 plays a major role in cancer progression and metas-
tasis through activation of various genes that are linked to
regulation of angiogenesis, cell survival, and energy
Forest plot of the HIF-1  1772 C/T polymorphism and cancer risk [T versue C and TT versus (CT+CC)]igure 1
Forest plot of the HIF-1  1772 C/T polymorphism and cancer risk [T versue C and TT versus (CT+CC)]. Results 
from the analysis on all available studies.Page 5 of 10
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to be implicated in the development and progression of
cancer [5,6]. The polymorphisms analyzed in the present
study consist of C to T and G to A nucleotide substitutions
at positions 1772 and 1790 of the exon 12 of the HIF-1
gene [5,6]. Because a study by Tanimoto et al [6] showed
that both of the substitutions displayed an increased
transactivation capacity of HIF-1α in vitro, the presence of
the variant alleles might be associated with increased can-
cer susceptibility. However, studies focusing on the asso-
ciation of the HIF-1  gene polymorphism with cancer
susceptibility had controversial conclusions [5,6,8-22].
The lack of concordance across many of these studies
reflects limitation in the studies, such as small sample
sizes, ethnic difference and research methodology. Meta-
analysis is a powerful tool for summarizing the results
from different studies by producing a single estimate of
the major effect with enhanced precision. It can overcome
the problem of small sample size and inadequate statisti-
cal power of genetic studies of complex traits, and provide
more reliable results than a single case-control study [27].
In this meta-analysis, we investigated the association
between the HIF-1  1772 C/T and 1790 G/A polymor-
phism and cancer risk. The subgroup analyses stratified by
cancer types, ethnicity, and gender were also performed.
For the HIF-1  1772 C/T polymorphism, our meta-analy-
sis on the available studies showed that the T allele and
genotype TT were significantly associated with increased
cancer risk. These associations were very robust, which did
not vary materially when the sensitivity analyses (exclu-
sion the study with controls not in HWE) were performed.
Forest plot the HIF-1  1772 C/T polymorphism and cancer risk in Caucasians [TT versus (CT+CC)]igure 2
Forest plot the HIF-1  1772 C/T polymorphism and 
cancer risk in Caucasians [TT versus (CT+CC)]. A. 
Results from the analysis on all studies of Caucasians. B. 
Results from the sensitivity analysis (exclusion of the studies 
with controls not in Hardy-Weinberg equilibrium).
Forest plot the HIF-1  1772 C/T polymorphism and cancer risk in female subjects [TT versus (CT+CC)]igure 3
Forest plot the HIF-1  1772 C/T polymorphism and 
cancer risk in female subjects [TT versus (CT+CC)]. 
A. Results from the analysis on all studies of female subjects. 
B. Results from the sensitivity analysis (exclusion of the stud-
ies with controls not in Hardy-Weinberg equilibrium).Page 6 of 10
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Caucasians and female subjects. Only female specific can-
cers were included in female subgroup in our meta-analy-
sis, which indicates that the genotype TT is significantly
associated with an increased risk for female specific can-
cers. The molecular basis of gender specific effect of the
HIF-1  1772 C/T polymorphism on cancers is unclear.
Studies have shown that estrogen can induce the expres-
sion of HIF-1  [28,29]. The substitution of C to T at posi-
tions 1772 of the exon 12 of the HIF-1  gene further
increase the transactivation capacity of the HIF-1  gene
and thus promote the development of female specific can-
cers. We also observed a marginally significant association
between the genotype TT and increased cancer risk in East
Asians. However, subjects with mutant homozygotes were
only detected in two studies of East Asians. The CI for this
subgroup was very wide, and the association could have
been caused by chance. More studies based on larger pop-
ulation should be conducted to further examine this asso-
ciation.
For the HIF-1  1790 G/A polymorphism, the meta-analy-
sis on all studies showed no evidence that the HIF-1  1790
G/A polymorphism was significantly associated with
increased cancer risk. We also performed the stratification
analyses by gender, ethnicity, and cancer types. The
pooled ORs for allelic frequency comparison and domi-
nant model comparison suggested the 1790 G/A poly-
morphism was significantly associated with an increased
cancer risk in Caucasians. However, the sensitivity analy-
sis did not suggest this association. Because the results
from the sensitivity analysis were more valid, our meta-
analysis does not strongly suggest the association between
the HIF-1  1790 G/A polymorphism and cancer risk in
Caucasians [23]. The pooled effects for allelic frequency
comparison and dominant model comparison suggested
a significant association between the HIF-1  1790 G/A
polymorphism and a decreased breast cancer risk. Because
the conclusion is inconsistent with the general under-
standing that the 1790 A alleles enhances HIF-1  transcrip-
tional activity and the presence of the variant allele might
be associated with increased cancer susceptibility, we fur-
ther performed the meta-analysis for the other cancers to
detect the specific effects of cancer type [6]. The results
suggested a significant association between the A allele
and increased cancer risk in other cancers. A marginal
association between the 1790 G/A polymorphism and
increased cancer risk in other cancers was also detected
under dominant model. However, the reanalysis after
exclusion the studies with controls not in HWE did not
suggest these associations. Our meta-analysis does not
strongly support the association between the HIF-1  1790
G/A polymorphism and the cancer risk in other cancers.
The exact mechanism for the inverse association between
the HIF-1  1790 G/A polymorphism and breast cancer was
not clear. However, there were two factors that must be
considered. First, the frequency of the HIF-1  1790 A allele
was very low and only two studies were included in the














A versus G Overall 12 <0.00001 Random 1.61 (0.75, 3.45) 0.22
Overall in HWE 11 0.0002 Random 1.32 (0.54, 3.24) 0.54
Caucasian 9 0.04 Random 3.08 (1.49, 6.36) 0.002
Caucasian in HWE 8 0.02 Random 2.15 (0.66, 7.02) 0.20
East Asian 2 0.33 Fixed 0.58 (0.24, 1.40) 0.23
Female* 5 0.07 Random 0.65 (0.07, 6.05) 0.71
Male (prostate cancer)** 2 0.64 Fixed 0.96 (0.49, 1.90) 0.91
Breast cancer 2 0.45 Fixed 0.28 (0.08,0.90) 0.03
Other cancers 10 0.0004 Random 2.31 (1.12, 4.75) 0.02
Other cancers in HWE 9 0.002 Random 1.97 (0.79, 4.90) 0.15
(AA+AG) versus GG Overall 12 <0.00001 Random 1.56 (0.66, 3.65) 0.31
Overall in HWE 11 0.0004 Random 1.25 (0.53, 2.97) 0.61
Caucasian 9 0.002 Random 2.60 (1.03, 6.59) 0.04
Caucasian in HWE 8 0.004 Random 1.80 (0.50, 6.54) 0.37
East Asian 2 0.41 Fixed 0.61 (0.25, 1.51) 0.29
Female* 5 0.08 Random 0.68 (0.07, 6.30) 0.74
Male (prostate cancer) ** 2 0.64 Fixed 0.96 (0.49, 1.90) 0.91
Breast cancer 2 0.41 Fixed 0.29 (0.09, 0.97) 0.04
Other cancers 10 <0.00001 Random 2.22 (0.95, 5.20) 0.06
Other cancers in HWE 9 0.002 Random 1.78 (0.72, 4.43) 0.21
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
* Only female specific cancers were included in the female subgroup.
** All male patients were the patients with prostate cancerPage 7 of 10
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to chance. Second, our meta-analysis suggests that carci-
nogenic mechanism may differ in different cancers and
HIF-1  1790 G/A polymorphism may exert varying effect.
More studies will be required to further examine the asso-
ciation.
The current meta-analysis has several limitations which
should be noted. First, the meta-analysis was based on the
aggregation of published case-control studies. 8 studies
did not clearly state the use of a matching design for cases
during the selection process of controls. The meta-analysis
was based on unadjusted estimates. A more precise analy-
sis should be conducted if more detailed individual data
were available, which would allow for an adjusted esti-
mate. Second, because of data limitation, we did not per-
form the stratification analyses by age, smoking, or other
variables. Third, several genotyping methods were used in
the eligible studies. The quality control of genotyping was
not well documented in some studies. Undoubtedly, the
limitations mentioned should affect our final conclu-
sions.
Conclusions
Our meta-analysis suggests that the HIF-1  1772 C/T pol-
ymorphism is significantly associated with higher cancer
risk, and the 1790 G/A polymorphism is significantly
associated with decreased breast cancer risk. The effect of
the 1772 C/T polymorphism on cancer especially exists in
Caucasians and female subjects. Only female specific can-
cers were included in female subgroup, which indicates
that the 1772 C/T polymorphism is significantly associ-
ated with an increased risk for female specific cancers. The
association between the 1790 G/A polymorphism and
lower breast cancer risk could be due to chance.
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